Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 6/20 | 0.79 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31279847 | 1.00 | KHK (0.79) | KHKSMYD3HPGDSACSS2MAPK14 | |
| SCHEMBL31279611 | 0.89 | KHK (1.00) | KHKSMYD3HPGDSACSS2MAPK14 | |
| SCHEMBL23711737 | 0.89 | KHK (1.00) | KHKSMYD3HPGDSACSS2MAPK14 | |
| SCHEMBL31279587 | 0.82 | KHK (1.00) | KHKHPGDSACSS2MAPK14TP53 | |
| SCHEMBL23711756 | 0.82 | KHK (1.00) | KHKHPGDSACSS2MAPK14TP53 | |
| SCHEMBL23711723 | 0.78 | KHK (1.00) | KHKHPGDSACSS2MAPK14 | |
| SCHEMBL31279982 | 0.78 | KHK (1.00) | KHKHPGDSACSS2MAPK14 | |
| Tert-Butyl Formate SCHEMBL28787428 | 0.73 | KHK (0.63) | KHKHPGDSACSS2MAPK14 | |
| SCHEMBL4175744 | 0.72 | RAB9A (0.53) | SMYD3 | |
| SCHEMBL23711773 | 0.71 | KHK (1.00) | KHKHPGDSMAPK14TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2021-09-09 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210275494-A1 | METHODS FOR FRUCTOKINASE MEDIATION OF ALCOHOL CRAVING AND ALCOHOL INDUCED LIVER DISEASE | KHK, GCK, FN3K | KHK 1/4885SMYD3 832/4885HPGDS 3068/4885 |
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | KHK, GCK, HK1 | KHK 1/4885SMYD3 2344/4885HPGDS 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.